Carrageenan, is a polymer derived from red seaweed found to be an effective antiviral in treating common cold. In present efficiency of Carrageenan against influenza virus, including H1N1 was studied. Results showed that the polymer directly binds to influenza viruses, effectively blocking the virus from attaching to cells and spreading further. In animal experiments, Carrageenan demonstrated equivalent efficacy when compared to the drug Tamiflu.
"Influenza viruses still represent a substantial threat to public health on a global scale and with increasing viral resistance to Tamiflu, the need for alternatives has never been greater," commented Dr. Andreas Grassauer, CEO and co-founder of Marinomed. "This study confirms that iota-carrageenan can be used as an alternative to neuraminidase inhibitors and should be further tested for prevention and treatment of influenza A in clinical trials in humans."